As there were possibly other factors in the tumor microenvironment involved in EGCG-mediated anti-tumor effects, we further investigated the proportions of MDSCs and T cells (both CD4+ and CD8+ T cells) in the peripheral blood, spleen and tumor tissues, to see whether these cells were influenced by the EGCG treatment. The gene discussed is CD8A; the disease is neoplasm.